{{orphan|date=December 2012}}
{{Chembox
| ImageFile = Urodilatin_-_Compound_Summary_(CID_16133394).svg
| ImageFile2 = Urodilatin_CDDANP-95-126.gif
| ImageSize =
| IUPACName =
| OtherNames =
| Section1 = {{Chembox Identifiers
|  CASNo = 115966-23-9
| CASNo_Comment = 
|  CASNo_Ref = {{cascite|<!-- also CAS verified -->|CAS}}
| CASNo2 = 118812-69-4 
| CASNo2_Comment = (ularitide) <!-- also CAS verified -->
|  PubChem = 16132416
|  ChemSpiderID = 17289074 
|  ChemSpiderID2 = 11209147
|  MeSHName=Urodilatin
| KEGG = C16000
| UNII = GZ8FA500J0
|  SMILES = CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)Cc2ccccc2)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C3CCCN3C(=O)C(C)NC(=O)C(C(C)O)N)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(Cc4ccccc4)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc5ccc(cc5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C
|  InChI = InChI=1S/C145H234N52O44S3/c1-11-72(6)112-137(238)171-60-106(208)172-73(7)113(214)177-86(40-41-103(146)205)122(223)190-95(63-198)116(217)170-61-108(210)175-88(51-70(2)3)114(215)169-62-109(211)176-100(133(234)187-92(56-104(147)206)127(228)193-97(65-200)130(231)186-91(54-77-27-16-13-17-28-77)126(227)180-82(31-20-45-163-142(153)154)119(220)189-94(139(240)241)55-78-36-38-79(204)39-37-78)68-243-244-69-101(134(235)185-90(53-76-25-14-12-15-26-76)115(216)168-58-105(207)167-59-107(209)174-80(29-18-43-161-140(149)150)117(218)182-87(42-50-242-10)123(224)188-93(57-110(212)213)128(229)181-85(124(225)196-112)34-23-48-166-145(159)160)195-132(233)99(67-202)194-131(232)98(66-201)192-120(221)83(32-21-46-164-143(155)156)178-118(219)81(30-19-44-162-141(151)152)179-125(226)89(52-71(4)5)184-129(230)96(64-199)191-121(222)84(33-22-47-165-144(157)158)183-135(236)102-35-24-49-197(102)138(239)74(8)173-136(237)111(148)75(9)203/h12-17,25-28,36-39,70-75,80-102,111-112,198-204H,11,18-24,29-35,40-69,148H2,1-10H3,(H2,146,205)(H2,147,206)(H,167,207)(H,168,216)(H,169,215)(H,170,217)(H,171,238)(H,172,208)(H,173,237)(H,174,209)(H,175,210)(H,176,211)(H,177,214)(H,178,219)(H,179,226)(H,180,227)(H,181,229)(H,182,218)(H,183,236)(H,184,230)(H,185,235)(H,186,231)(H,187,234)(H,188,224)(H,189,220)(H,190,223)(H,191,222)(H,192,221)(H,193,228)(H,194,232)(H,195,233)(H,196,225)(H,212,213)(H,240,241)(H4,149,150,161)(H4,151,152,162)(H4,153,154,163)(H4,155,156,164)(H4,157,158,165)(H4,159,160,166)/t72-,73-,74-,75+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,111-,112-/m0/s1
  }}
| Section2 = {{Chembox Properties
|  Formula = |C=145|H=234|N=52|O=44|S=3|
|  MolarMass = 3505.926
|  Appearance =
|  Density =
|  MeltingPt =
|  BoilingPt =
|  Solubility =
  }}
| Section3 = {{Chembox Hazards
|  MainHazards =
|  FlashPt =
|  Autoignition =
  }}
}}

'''Urodilatin''' is a [[hormone]] that causes [[Forced diuresis|diuresis]] through increasing [[renal blood flow]]. It is secreted in response to increased [[mean arterial pressure]] and increased blood volume from the cells of the [[distal tubule]] and [[collecting duct]]. It is important in [[oliguric]] patients (such as those with [[acute renal failure]] and [[chronic renal failure]]) as it lowers serum [[creatinine]] and increases [[urine]] output.

==Interactions of Urodilatin==
[[Atrial natriuretic peptide]] (CDD/ANP-99-126)<ref name="pmid2968281">{{cite journal | author = Gagelmann M, Hock D, Forssmann WG. | title = Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a [[peptidase]] from dog [[kidney cortex]] membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126). | journal = FEBS Lett. | volume = 20 | issue = 223(2) | pages = 249–54 | year = 1988 | month = June | pmid = 2968281 | doi = 10.1016/0014-5793(88)80436-8 | url = }}</ref> is a hormone system of clinical importance. Urodilatin (CDD/ ANP-95-126) is a [[homologue]] [[natriuretic peptide]] that differs from CDD/ANP-99-126  which is excreted into the circulation via [[exocytosis]]. The [[prototype]] of the natriuretic hormones is [[cardiodilatin]]/[[atrial natriuretic peptide]] (CDD/ANP).<ref name="pmid8986039">{{cite journal | author = Meyer M, Stief CG, Becker AJ, Truss MC, Taher A, Jonas U, Forssmann WG. | title = The renal paracrine peptide system--possible urologic implications of urodilatin. | journal = World J Urol. | volume = 14 | issue = 2 | pages = 249–54 | year = 1988 | month = June | pmid = 8986039 | doi = 10.1007/BF00183118 | issn = 0724-4983 | url = }}</ref> The endocrine heart is composed of specific myo[[endocrine]] cells that synthesize and secrete the natriuretic peptide hormones which exhibit [[diuretic]], and [[vasorelaxant]] properties; secretion is the basis for a [[paracrine]] system regulating water and [[sodium]] [[reabsorption]].<ref name="pmid9792413">{{cite journal | author = Forssmann WG, Richter R, Meyer M. | title = The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. | journal = Histochem Cell Biol | volume = 110 | issue = 4 | pages =335–57  | year = 1998 | month = October | pmid = 9792413 | doi = 10.1007/s004180050295 | url = }}</ref> Research efforts since the early 1980s have studied their effects on [[electrolyte]] [[homeostasis]].<ref name="pmid7702187">{{cite journal | author = Meyer M, Schulz-Knappe P, Kuse ER, Hummel M, Hetzer R, Pichlmayr R, Forssmann WG. | title = [Urodilatin. Use of a new peptide in intensive care] | journal = Anaesthesist. | volume = 44 | issue = 2 | pages =81–91  | year = 1995 | month = February | pmid = 7702187 | doi =  | url = }}</ref> When administered [[intravenous]]ly, URO induces strong [[diuresis]] and [[natriuresis]] with tolerable [[hemodynamic]] side effects.<ref name="pmid8702053">{{cite journal | author = Kuse ER, Meyer M, Constantin R, Oldhafer K, Schlitt HJ, Schulz-Knappe P, Uberbacher HJ, Pichlmayr R, Forssmann WG. | title = [Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation] | journal = Anaesthesist. | volume = 45 | issue = 4 | pages =351–8  | year = 1996 | month = April | pmid = 8702053 | doi =  | url = }}</ref> Urodilatin is localized in the [[kidney]], differentially processed (involved in the regulation of body fluid volume and water-electrolyte excretion, while circulating), and secreted into the urine.<ref name="pmid8702053"/> As a consequence, urodilatin is involved in drug development along with the [[prohormone]] CDD/ANP-1-126 <ref name="pmid8986039">{{cite journal | author = Meyer M, Stief CG, Becker AJ, Truss MC, Taher A, Jonas U, Forssmann WG. | title = The renal paracrine peptide system--possible urologic implications of urodilatin. | journal = World J Urol. | volume = 14 | issue = 2 | pages = 249–54 | year = 1988 | month = June | pmid = 8986039 | doi =  10.1007/BF00183118| issn = 0724-4983 | url = }}</ref> and [[cardiodilatin]] CDD/ANP-99-126.<ref name="pmid9792413">{{cite journal | author = Forssmann WG, Richter R, Meyer M. | title = The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. | journal = Histochem Cell Biol. | volume = 110 | issue = 4 | pages = 335–57 | year = 1998 | month = October | pmid = 9792413 | doi = 10.1007/s004180050295  | url = }}</ref> A message for the [[preprohormone]] is transcribed in the heart and kidneys from the gene of NP type A, resulting in a [[cGMP]]-dependent signal transduction which induces diuresis and natriuresis,<ref name="pmid9512977">{{cite journal | author = Meyer M, Richter R, Forssmann WG. | title = Urodilatin, a natriuretic peptide with clinical implications. | journal = Eur J Med Res. | volume = 3 | issue = 1–2 | pages = 103–110 | year = 1998 | month = October | pmid = 9512977 | doi =   | url = }}</ref> differentially processed to a peptide of 32 [[amino acid]]s from the same precursor as renal ANP, may not be identical to the circulating cardiac hormone ANP.<ref name="pmid11476735">{{cite journal | author = Forssmann W, Meyer M, Forssmann K. | title = The renal urodilatin system: clinical implications. | journal = Cardiovasc Res. | volume = 51 | issue = 3 | pages = 450–62 | year = 2001 | month = August | pmid = 11476735 | doi = 10.1016/S0008-6363(01)00331-5  | url = }}</ref> The kidneys produce their own natriuretic 32-residue peptide. Urodilatin renal natriuretic peptide potency equals or exceeds that of [[Atriopeptin]] [ANP-(99-126)], the prototype of cardiodilatin.<ref name="pmid1836308">{{cite journal | author = Goetz KL. | title = Renal natriuretic peptide (urodilatin?) and atriopeptin: evolving concepts. | journal = Am J Physiol.  | volume = 261 | issue = 6 | pages = 921–32 | year = 1991 | month = December | pmid = 1836308 | doi =  | url = }}</ref> Atriopeptin is only of trivial importance in the regulation of sodium excretion during normal living conditions.<ref name="pmid7508039">{{cite journal | author = Goetz KL. | title = Is urodilatin (rather than atriopeptin) the primary natriuretic peptide of the ANP family? | journal = J Cardiovasc Pharmacol. | volume = 22 | issue = 6 | pages = 911–913 | year = 1993 | month = December | pmid = 7508039 | doi =   | url = }}</ref> Urodilatin is little affected by renal [[enzymes]] that inactivate [[atriopeptin]], as the kidney elutes with urodilatin rather than with ANP.<ref name="pmid1966524">{{cite journal | author = Goetz K, Drummer C, Zhu JL, Leadley R, Fiedler F, Gerzer R. | title = Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. | journal = J Am Soc Nephrol.  | volume = 1 | issue = 6 | pages = 867–74 | year = 1990 | month = December | pmid = 1966524 | doi =  | ISSN = 1533-3450 | url = }}</ref> The degradation rates of ([[i125|125I]])-urodilatin and [125I]-ANP by pure [[recombinant]] NEP (rNEP) were compared. [[Phosphoramidon]], a potent inhibitor of NEP, completely protected both peptides from metabolism by rNEP.<ref name="pmid7812611">{{cite journal | author = Abassi ZA, Golomb E, Agbaria R, Roller PP, Tate J, Keiser HR. | title = Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11. | journal = Br J Pharmacol. | volume = 113 | issue = 1 | pages = 204–208 | year = 1994 | month = September | pmid = 7812611 | doi =  | pmc= 1510039 | url = }}</ref> Urodilatin, has a four-residue extension at the [[N-terminus]] [[neutral endopeptidase]]-24.11 (NEP)  plays a physiological role in metabolizing [[atrial natriuretic peptide]], and C-type natriuretic peptide ([[prohormone]]) degraded the bioactive peptides at about half the rate though the [[C-terminal]] that compete with natriuretic peptides for [[hydrolysis]] by [[neutral endopeptidase]].<ref name="pmid8097089 ">{{cite journal | author = Kenny AJ, Bourne A, Ingram J. | title = Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. | journal = Biochem J. | volume = 1 | issue =291 | pages = 83–8 | year = 1998 | month = April | pmid = 8097089  | doi = | pmc=1132484  | url = }}</ref>

==References==
{{reflist}}

[[Category:Hormones of the kidneys]]